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Abstract
Mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral
blood is a complex mechanism that involves adhesive and chemotactic interactions of
HSCs as well as their bone marrow microenvironment. In addition to a number of non-
genetic factors, genetic susceptibilities also contribute to the mobilization outcome. Identifi-
cation of genetic factors associated with HSC yield is important to better understand the
mechanism behind HSC mobilization. In the present study, we enrolled 148 Korean partici-
pants (56 healthy donors and 92 patients) undergoing HSC mobilization for allogeneic or
autologous HSC transplantation. Among a total of 53 polymorphisms in 33 candidate genes,
one polymorphism (rs11264422) in relaxin/insulin-like family peptide receptor 4 (RXFP4)
gene was significantly associated with a higher HSC yield after mobilization in Koreans.
However, in a set of 101 Europeans, no association was found between circulating CD34+
cell counts and rs11264422 genotype. Therefore, we suggest that the ethnic differences in
subjects’ genetic background may be related to HSC mobilization. In conclusion, the relaxin
—relaxin receptor axis may play an important role in HSC mobilization. We believe that the
results of the current study could provide new insights for therapies that use relaxin and
HSC populations, as well as a better understanding of HSC regulation and mobilization at
the molecular level.
Introduction
Hematopoietic stem cell (HSC) mobilization is a complex process that involves chemotactic
factors, proteases, and adhesive molecules in bone marrow (BM) niches [1–3]. There is wide
inter-individual variability in response to mobilization, and the outcome is hardly predictable
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despite several known demographic or clinical risk factors such as the following: age, sex, body
mass index (BMI), ethnicity, diagnosis, and extent and duration of prior chemotherapy [4–8].
Inter-individual variation of HSC mobilization yield can be explained by a multifactorial
model consisting of environmental and multiple genetic factors. Genetic contribution to
mobilizing capacity is further supported by the fact that the second mobilization in the same
donor typically yields similar results to those from the first mobilization [9,10].
Previous studies have reported genetic associations between single nucleotide polymor-
phisms (SNPs) and HSC mobilization yield [11–15]. Most of these SNPs are located in gene
encoding molecules with known functional significance in the mobilization pathway, includ-
ing C-X-C motif chemokine ligand 12 (CXCL12), vascular cell adhesion molecule 1 (VCAM1),
CD44 (CD44), and colony stimulating factor 3 receptor (CSF3R) [11–15]. However, some of
the results were not replicated in subsequent studies [11,16,17], and the responsible gene
remains elusive.
Recent genome-wide association studies have shown that various hematologic traits of
white blood cells (WBC), red blood cells, platelets, and CD34+ cells are highly heritable
[18,19]. Previous studies have also indicated that each WBC subtype shares some associations
which are probably attributable to shared process of differentiation and maintenance in BM
and peripheral blood (PB) [18,20]. Therefore, we hypothesized that genetic factors associated
with WBC count, neutrophil count, and circulating CD34+ cell count could also contribute to
the regulation and migration of HSCs in BM niches and in PB.
The aim of this study was to identify genetic factors associated with HSC collection yield
after mobilization in Korean population. We also attempted to determine whether our finding
could be applied to other ethnic group of European ancestry.
Methods
Participants
A total of 148 Korean subjects, including 56 healthy donors for allogeneic HSC transplantation
and 92 patients with hematologic disorders for autologous HSC transplantation, were prospec-
tively recruited for this study. The European set was recruited to confirm the applicability
of our findings, and consisted of 101 healthy donors of European ancestry from Germany.
This study was approved by the institutional review board (IRB) of the Severance Hospital,
Yonsei University College of Medicine (IRB No. 4-2013-0145). Written informed consent was
obtained from all participants, in accordance with the Declaration of Helsinki.
Mobilization and HSC collection
For healthy donors, standard mobilization protocol was used with G-CSF (filgrastim 10 μg/kg
daily), and collection was initiated on the fifth day after G-CSF initiation. Mobilization for
patients undergoing autologous HSC transplantation was performed using G-CSF only or che-
motherapy followed by G-CSF. Apheresis started when the PB leukocyte count reached 3.0 x
109/L after leukocyte nadir, in the case of combination with chemotherapy. Peak circulating
CD34+ cell count (/μL), collected just before apheresis, was assessed using a Stem-Kit (Beck-
man Coulter, Miami, FL, USA) for the Korean set and with a BD Stem Cell Enumeration kit
(BD Biosciences, San Jose, CA, USA) for the European set. The CD34+ cell content in the first
apheresis product was enumerated in 122 participants in the Korean set, and two additional
outcomes were evaluated: total CD34+ cell count per donor body weight (/kg) obtained from
the first apheresis; and CD34+ cell count (/μL) from the first apheresis product.
Relaxin receptor polymorphism and HSC mobilization
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Selection of target polymorphisms in candidate genes
To determine whether previously reported genetic associations with HSC yield might be
applied to Koreans, we selected four common polymorphisms (rs1801157, rs1041163, rs13347,
and rs3917924) in the following four genes: CXCL12, VCAM1, CD44, and CSF3R [11–17]. One
polymorphism (rs2680880) in CXCR4 was not included, as it was not found in East Asians
(http://www.1000genomes.org/) [12]. To identify more candidate genes, we searched the liter-
ature for SNPs that are associated with WBC, neutrophil, or CD34+ cell counts [19–28] (Fig
1). Among the 64 additional SNPs, 15 with East Asian minor allele frequency of less than 0.05
were removed. Candidate genes were adopted from the literature or selected based on the
functional relatedness to mobilization mechanism, such as cytokines, chemokines, proteases,
and adhesion molecules (http://www.uniprot.org/) [2,3]. In total, 53 SNPs were selected for
genotyping (Table 1).
SNP genotyping
Genomic DNA was extracted from PB leukocytes using the QIAamp DNA Blood Mini Kit
(Qiagen, Venlo, The Netherlands). The primer sequences for polymerase chain reaction
(PCR) amplification and sequencing were designed using Primer3 software [29]. PCR was per-
formed on 100 ng of genomic DNA, and sequencing was carried out using the BrightDye Ter-
minator Cycle Sequencing Kit (Nimagen, Nijmegen, The Netherlands) on ABI 3500 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA). The results were compared with refer-
ence sequences using Sequencher 5.1 software (Gene Codes Corp., Ann Arbor, MI, USA).
Quality of data was assessed using PHRED score for each base call [30]. The threshold for
PHRED score was 20, based on the manufacturer’s instructions. In case of result with inade-
quate quality, sequencing was repeated and all genotype of tested locus were determined (no
missing genotype data).
Statistical analysis
Following the Kolmogorov—Smirnov normality test, natural log transformation was applied
on continuous outcome variables with skewed distribution for analysis. The association
between continuous variables (age and BMI) and mobilization outcomes (CD34+ cell count in
PB, total CD34+ cells/kg, and CD34+ cells in a product) were analyzed using Pearson correla-
tion. The association between categorical variables (sex, diagnosis, BM involvement of disease,
chemotherapy regimen history, mobilization protocol, and SNP genotype), and mobilization
outcomes were analyzed using an independent two-sample t-test (for two categories) and anal-
ysis of variance (for three categories). Three subgroups were established for the genotype of
each polymorphism: homozygous for the major allele, heterozygous and homozygous for the
minor allele. We also tested three genetic models (dominant, recessive, and additive) using
biallelic marker coding. SNPs with a raw P< 0.05 in analysis with all three mobilization out-
comes were included in multivariate linear regression analysis. Additional variables related to
patient demographics or clinical history with P< 0.05 shown in univariate analysis were
included in multivariate analysis. Finally, the following variables were included in multivariate
analysis according to each mobilization outcome: 1) CD34+ cell count in PB: sex, diagnosis,
chemotherapy regimen history, and rs11264422 (RXFP4) genotype; 2) total CD34+ cells/kg:
sex and RXFP4 genotype; and 3) CD34+ cell count in a product: sex, BMI, diagnosis, and
RXFP4 genotype. False discovery rate (FDR) controlling procedure was used to adjust for mul-
tiple testing according to the genetic model [31]. P values < 0.05 were considered significant,
and P values< 0.2 after FDR adjustment were considered to have a tendency [32]. Statistical
analysis was performed using SPSS Statistics version 23.0.0 (IBM Corp., Armonk, NY, USA).
Relaxin receptor polymorphism and HSC mobilization
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Fig 1. Flow diagram of target polymorphism selection. The diagram indicates inclusion and exclusion criteria for selection of
target polymorphism.
https://doi.org/10.1371/journal.pone.0179986.g001
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Table 1. List of 53 polymorphisms in 33 genes included in this study.
rs ID Chromosome Location (GRCh38.
p2)
Candidate
gene
Distance to gene Protein function
rs11121242 1p36.23 8846242 RERE 20 kb
downstream
Control of cell survival
rs6577536 1p36.23 8850051 RERE 23 kb
downstream
Control of cell survival
rs11590606 1p36.23 8857610 RERE 31 kb
downstream
Control of cell survival
rs10864368 1p36.23 8858254 RERE 32 kb
downstream
Control of cell survival
rs3917924 1p34.3 36480052 CSF3R Intron2 Cell adhesion and chemotaxis
rs1041163 1p21.2 100718269 VCAM1 1 kb upstream Cell adhesion and migration
rs6702883 1p21.1 104700458 intergenic
rs4311917 1p13.3 107183121 NTNG1 Intron2 Controlling axon growth
rs345275 1p13.3 107951181 VAV3 Intron1 Regulation of cell adhesion
rs2365669 1p13.2 111820023 KCND3 Intron2 Subunit of potassium channel
rs7523839 1p13.2 115630459 VANGL1 11 kb upstream Multicellular organism development
rs850610 1p13.1 116406090 ATP1A1-AS1 Exon 3 Non-coding RNA
rs10923929 1p12 119963373 NOTCH2 Intron11 Stem cell population maintenance
rs11240089 1q21.1 147588715 BCL2 Intron1 Cell migration
rs4657616 1q23.1 159001296 ACKR1 202 kb upstream Chemokine receptor
rs2518564 1q23.1 159092646 ACKR1 111 kb upstream Chemokine receptor
rs12075 1q23.1 159205564 ACKR1 Exon 2 Chemokine receptor
rs12740969 1q21.3 154514584 TDRD10 Intron4 Nucleotide binding
rs11264422 1q22 155938032 RXFP4 3 kb upstream Relaxin-3 receptor
rs1962508 1q23.3 161975629 DDR2 655 kb upstream Cell migration and remodeling of the extracellular matrix
rs2806424 1q23.3 162721669 DDR2 Intron4 Cell migration and remodeling of the extracellular matrix
rs6426893 1q23.3 165058105 intergenic
rs919679 1q24.1 166287925 intergenic
rs6734238 2q13 113083453 IL1F10 7 kb upstream Cytokine
rs10932765 2q35 218234761 ARPC2 Intron5 Cytoskeleton constituent
rs16850408 4q13.3 74067090 CXCL2 29 kb upstream Chemokine
rs546829 4q13.3 74090655 CXCL2 6 kb upstream Chemokine
rs9131 4q13.3 74097332 CXCL2 Exon 4 Chemokine
rs7667376 4q13.3 74102173 CXCL2 2 kb downstream Chemokine
rs1371799 4q13.3 74112120 CXCL2 12 kb
downstream
Chemokine
rs7686861 4q13.3 74132767 CXCL2 33 kb
downstream
Chemokine
rs2517524 6p21.33 31057936 HCG22 Intron3 Non-coding RNA
rs2853946 6p21.33 31279426 HLA-B 74 kb upstream Regulation of immune response
rs2844503 6p21.33 31474954 HLA-B 117 kb
downstream
Regulation of immune response
rs6936204 6p21.32 32249315 intergenic
rs5020946 6p21.32 32482312 BTNL2 73 kb
downstream
Regulation of T-cell proliferation
rs4895441 6q23.3 135105435 MYB 75 kb upstream Control of proliferation and differentiation of hematopoietic
progenitor cells
rs12660713 6q23.3 135196858 MYB Intron9 Control of proliferation and differentiation of hematopoietic
progenitor cells
rs976760 7p21.2 14234028 DGKB Intron22 Intracellular signal transduction
(Continued )
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FDR adjusted P values were calculated using Microsoft Exel 2010 (Microsoft Corporation,
Redmond, WA, USA).
Results
Patient characteristics
Patient characteristics are summarized in Table 2. The group consisted of individuals who
were diagnosed with acute leukemia (n = 8), non-Hodgkin lymphoma (n = 50), multiple mye-
loma (n = 33), and sarcoma (n = 1). On the first day of apheresis, the median circulating CD34
+ count was 44 cells/μL in the Korean set and 93 cells/μL in the European set (healthy donors
only for the latter).
Relaxin/insulin-like family peptide receptor 4
Of the 53 SNPs, only one polymorphism (rs11264422) made a significant difference in the
three HSC mobilization outcomes of the Korean set (Table 3). The rs11264422 genotype,
located 3 kb upstream of the relaxin/insulin-like family peptide receptor 4 (RXFP4) gene, was
significantly associated with circulating CD34+ cells/μL (raw P = 0.03), total CD34+ cells/kg
(raw P = 0.008), and product CD34+ cells/μL (raw P = 0.003) (Fig 2). Three patients (two with
lymphoma and one with multiple myeloma) who were homozygous for a minor allele (AA
genotype) showed remarkably higher mobilization outcomes compared to both the 25 patients
who were heterozygous (TA genotype) and the 120 who were homozygous (TT genotype) for
the major allele. Moreover, the presence of A allele (TA+AA genotypes) showed significant
association with higher CD34+ cells/μL in a product (raw P = 0.02). Superior mobilizers
(defined as> 200 circulating CD34+ cells/μL) had the highest frequency (66.7%) of the AA
genotype, followed by TA (12.0%) and TT (5.8%) genotypes (Fig 3). In contrast, poor mobili-
zers (defined as< 20 circulating CD34+ cells/μL) had a higher frequency of the TT (25.0%)
than TA (12.0%) genotype. However, for rs11264422 genotyping using the European set, the
circulating CD34+ cell count did not differ between each genotype subgroup. SNP was at
Hardy—Weinberg equilibrium in both Korean and European sets.
Table 1. (Continued)
rs ID Chromosome Location (GRCh38.
p2)
Candidate
gene
Distance to gene Protein function
rs445 7q21.2 92779056 CDK6 Intron2 Hematopoietic stem cell differentiation and cell adhesion
rs2163950 8q24.21 129585339 CCDC26 Intron 1 Non-coding RNA
rs579459 9q34.2 133278724 ABO 3 kb downstream Blood group system
rs1801157 10q11.21 44372809 CXCL12 Exon 4 Chemokine
rs13347 11p13 35231725 CD44 Exon 18 Cell adhesion and migration
rs2183383 11p11.12 50279041 PTPRJ 2 Mb downstream Regulation of cell adhesion
rs17609240 17q21.1 39954436 GSDMA 8 kb upstream Pyroptosis mediator
rs3894194 17q21.1 39965740 GSDMA Exon3 Pyroptosis mediator
rs3859192 17q21.1 39972395 GSDMA Intron6 Pyroptosis mediator
rs4065321 17q21.1 39987295 PSMD3 Intron3 Regulatory subunit of the 26 proteasome
rs4794822 17q21.1 40000459 CSF3 14 kb upstream Cytokine that controls granulocyte production
rs8078723 17q21.1 40010626 CSF3 4 kb upstream Cytokine that controls granulocyte production
rs8065443 17q21.1 40052687 MED24 Intron3 Component of transcriptional coactivator complex
rs2072910 20p12.2 9384656 PLCB4 Intron13 Intracellular signal transduction
https://doi.org/10.1371/journal.pone.0179986.t001
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Univariate and multivariate analyses of host factors and mobilization
outcomes
In univariate analysis, the circulating CD34+ cell count after mobilization was associated with
sex, diagnosis, history of multiple chemotherapy regimens, and RXFP4 genotype in the Korean
population (Table 4). In the European set, only a low BMI showed significant correlation with
a low circulating CD34+ cell count (P< 0.001). In the Korean set, the total CD34+ cell count/
kg was associated with sex and RXFP4 genotype, while the CD34+ cell count in a product was
associated with sex, BMI, diagnosis, and RXFP4 genotype.
Multivariate linear regression analysis revealed that female sex, diagnosis of acute leukemia,
history of multiple chemotherapy regimens, and RXFP4 genotype (TT and TA) remained
independently associated with lower circulating CD34+ cell count after mobilization in the
Korean set (Table 5). Female sex and RXFP4 genotype (TT and TA) showed consistent signifi-
cance when analyzed with other outcome variables, i.e., total CD34+ cell count/kg and CD34
+ cell count in a product.
Table 2. Characteristics of the participants in this study.
n (%)/median (interquartile ranges)
Characteristics Korean set European set
No. 148 101
Age (yr) 46 (32–56) 32 (26–42)
Sex
Female 63 (42.6) 26 (25.7)
Male 85 (57.4) 75 (74.3)
Body-mass index (kg/m2) 24.4 (21.5–26.1) 24.5 (22.4–28.0)
Diagnosis
Healthy donor 56 (37.8) 101 (100)
Acute leukemia 8 (5.4) -
Non-Hodgkin lymphoma 50 (33.8) -
Multiple myeloma 33 (22.3) -
Sarcoma 1 (0.7) -
BM involvement of disease
Present 51 (34.5) -
Absent 97 (65.5) -
Chemotherapy regimen history
Multiple regimens (three or more) 9 (6.1) -
One or two regimens 139 (93.9) -
Mobilization
Chemotherapy and G-CSF 80 (54.1) -
G-CSF only 68 (45.9) 101 (100)
CD34+ cell count (/μL) in PB 44 (22–84) 93 (67–116)
First apheresis product*
CD34+ cell count (/μL) 1,418 (591–2,330) -
CD34+ cell count/kg donor (×106) 3.54 (1.69–6.91) -
PB, peripheral blood
aCD34+ cell count in an apheresis product was measured in 122 participants.
https://doi.org/10.1371/journal.pone.0179986.t002
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Discussion
In this study, we found that rs11264422 genotype, located in the promoter flanking region of
RXFP4, has a significant effect on HSC mobilization. The RXFP4 gene encodes relaxin-3
receptor 2, which is a receptor for relaxin-3 and is expressed in various tissues including BM
[33]. Relaxin-3 is a member of the insulin/relaxin superfamily of peptide hormones [34].
Segal et al. revealed that the relaxin hormone mobilizes BM-derived CD34+ endothelial pro-
genitor cells into circulation, and their effect is mediated by the relaxin receptor [35]. The
role of relaxin and its receptor-mediated pathway in HSC mobilization, as well as their asso-
ciation with the inter-individual variation of mobilization yield, can be hypothesized based
on such observation.
Table 3. Association of rs11264422 with mobilization outcomesa.
Genotype Korean set European set
CD34+ cells/μL in PB CD34+ cells/kg (×106) CD34+ cells/μL in a product CD34+ cells/μL in PB
n Mean ± SD Raw P FDR P n Mean ± SD Raw P FDR P n Mean ± SD Raw P FDR P n Mean ± SD P
TT 120 3.60 ± 1.28 0.03b* 0.808b 98 1.11 ± 1.33 0.008b* 0.424b 98 7.10 ± 1.39 0.003b* 0.159b*** 11 4.54 ± 0.31 0.5b
TA 25 3.85 ± 1.17 21 1.47 ± 1.25 21 7.58 ± 1.31 41 4.30 ± 0.68
AA 3 5.51 ± 0.51 3 3.44 ± 0.51 3 9.72 ± 0.45 49 4.41 ± 0.58
TT+TA 145 3.55 ± 1.41 0.01c* 0.5c 119 1.20 ± 1.35 0.008c* 0.4c 119 7.25 ± 1.42 0.003c* 0.15c*** 52 4.44 ± 0.54 0.3c
AA 3 5.51 ± 0.51 3 3.44 ± 0.51 3 9.72 ± 0.45 49 4.30 ± 0.63
TT 120 3.60 ± 1.28 0.1c 0.728c 98 1.11 ± 1.33 0.05c** 0.795c 98 7.10 ± 1.39 0.02c* 0.711c 11 4.50 ±0.31 0.4c
TA+AA 28 4.02 ± 1.23 24 1.71 ± 1.35 24 7.84 ± 1.43 90 4.36 ± 0.63
TT+AA 123 3.65 ± 1.33 0.5c 0.995c 101 1.23 ± 1.37 0.4c 0.938c 101 7.22 ± 1.44 0.3c 0.88c 60 4.41 ± 0.58 0.5c
TA 25 3.84 ± 1.17 21 1.47 ± 1.25 21 7.57 ± 1.31 41 4.35 ± 0.63
PB, peripheral blood; SD, standard deviation; FDR, adjusted P value using false discovery rate controlling procedure
aNatural log transformation was applied to mobilization outcomes due to skewed distribution.
bAnalysis of variance
Independent two-sample t-test
*P< 0.05
**P = 0.05
***P< 0.2 after FDR adjustment
https://doi.org/10.1371/journal.pone.0179986.t003
Fig 2. Correlations between rs11264422 genotype and continuous outcomes. There were significant associations between
rs11264422 genotype and (A) circulating CD34+ cells/μL (raw P = 0.03), (B) total CD34+ cells/kg (raw P = 0.008), and (C) product CD34
+ cells/μL (raw P = 0.003) in the Korean set (gray-colored bar). However, no statistically significant association was found between
rs11264422 genotype and circulating CD34+ cells/μL in the European set (solid-lined bar). Mobilization outcomes were applied natural log
transformation, due to the skewed distribution.
https://doi.org/10.1371/journal.pone.0179986.g002
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The FDR-adjusted P-values for rs11264422 were above the significance threshold
(P = 0.05). However, we considered P< 0.2 after FDR adjustment as having a tendency for
association. Given that the sample size was inadequate compared with the number of genes,
we sought to find a possible exploratory factor. We determined three different mobilization
outcomes and found consistent genes in all three. We then decided that the P-value of
rs11264422 showed a meaningful trend, and wanted to suggest a further study. Therefore, we
would like to conduct a confirmatory study using a larger number of patients.
The rs11264422 polymorphism has been associated with lower WBC counts in individuals
of African, but not European, ancestry [28]. In our study, rs11264422 genotype was associated
with HSC yield in Koreans but not in Europeans. Interestingly, the frequency of AA homozy-
gote genotype is low in East Asians (1–4% in Japanese and Chinese) and Africans (0.2%), but
distinctly higher in Europeans (43%). Moreover, in a previous randomized controlled trial in
Japan, a higher baseline WBC count was associated with a lower incidence of poor mobiliza-
tion [36]. Therefore, we infer that the mechanism involved in HSC mobilization differs by eth-
nic groups, and rs11264422 genotype is associated with the HSC mobilization yield as well as
the baseline WBC count in certain populations. Moreover, associations between the four poly-
morphisms in CXCL12, VCAM1, CD44, and CSF3R and mobilization outcome were not repli-
cated in our study. Previous studies have already noted discrepancies in genetic associations,
which were likely attributed to differences in ethnicity, diagnosis, number of study partici-
pants, and definition of outcome [13–17]. In particular, most of the previous studies had
Fig 3. The rs11264422 genotype distribution of participants in the Korean set, classified by circulating CD34+ cell count. Superior
mobilizers (> 200 cells/μL) had 66.7%, 12.0%, and 5.8% frequency rates in AA, TA, and TT genotypes, respectively. Poor mobilizers (< 20
cells/μL) had 25.0% and 12.0% frequency rates in TT and TA genotypes, respectively.
https://doi.org/10.1371/journal.pone.0179986.g003
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targeted those of European ancestry, whereas our study is the first to target the East Asian pop-
ulation. Therefore, our results suggest that there are significant differences in molecular mech-
anisms underlying HSC mobilization between different ethnic groups. Our preliminary data
warrant further validation with larger cohorts of various population subgroups.
The therapeutic effect of circulating CD34+ cells has been demonstrated in hematologic
disorders and cardiovascular diseases [37,38]. In this context, the promotion of vasculogenesis
is thought to be a mechanism for efficacy of CD34+ progenitor cells [19]. Notably, serelaxin,
which is a recombinant human relaxin-2, has demonstrated significant treatment effects on
acute heart failure in a recent clinical trial [39]. The potential mechanisms behind beneficial
effects of serelaxin in acute heart failure include vasodilation, tissue healing from stimulation
of angiogenesis and stem cell survival, and remodeling of the extracellular matrix [40]. Fur-
thermore, a recent experimental study demonstrated that relaxin improves wound healing in
Table 4. Factors associated with mobilization outcomes in the univariate analysisa.
Variables Korean set European set
CD34+ cells/μL in PB CD34+ cells/kg (×106) CD34+ cells/μL in a
product
CD34+ cells/μL in PB
r, mean ± SD P value r, mean ± SD P value r, mean ± SD P value r, mean ± SD P value
Age (yr) -0.064 0.4b -0.014 0.9b 0.096 0.3b 0.007 0.9b
Sex 0.001c* 0.002c* <0.001c* 0.06c
Male 3.99 ± 1.20 1.87 ± 1.01 7.70 ± 1.42 4.47 ± 0.51
Female 3.34 ± 1.19 1.34 ± 0.77 6.65 ± 1.19 4.15 ± 0.78
Body-mass index (kg/m2) 0.155 0.06b 0.112 0.2b 0.204 0.02b* 0.343 <0.001b*
Diagnosis <0.001d* 0.08d 0.01d* -
Healthy donor 3.88 ± 0.57 1.74 ± 0.39 6.81 ± 0.58
Acute leukemia 2.07 ± 1.04 0.81 ± 0.55 6.16 ± 1.27
Non-Hodgkin lymphoma/sarcomae 3.73 ± 1.68 1.69 ± 1.22 7.61 ± 1.05
Multiple myeloma 3.87 ± 0.96 1.67 ± 0.95 7.61 ± 1.05
BM involvement of disease 0.2c 0.4c 0.4c -
Absent 3.80 ± 1.17 1.69 ± 0.94 7.16 ± 1.43
Present 3.55 ± 1.35 1.56 ± 0.96 7.37 ± 1.40
Chemotherapy regimen history 0.04c* 0.09c 0.3c -
One or two regimens 3.77 ± 1.22 1.68 ± 0.95 7.29 ± 1.41
Multiple regimens (three or more) 2.89 ± 1.27 1.14 ± 0.85 6.72 ± 1.52
Mobilization 0.8c 0.9c 0.7c -
G-CSF only 3.69 ± 1.28 1.64 ± 0.97 7.30 ± 1.45
Chemotherapy and G-CSF 3.74 ± 1.20 1.64 ± 0.93 7.19 ± 1.40
RXFP4 genotype 0.03d* 0.008d* 0.003d* 0.5d
TT 3.60 ± 1.28 1.11 ± 1.33 7.10 ± 1.39 4.54 ± 0.31
TA 3.85 ± 1.17 1.47 ± 1.25 7.58 ± 1.31 4.30 ± 0.68
AA 5.51 ± 0.51 3.44 ± 0.51 9.72 ± 0.45 4.41 ± 0.58
aNatural log transformation was applied to mobilization outcomes due to skewed distribution. Data were represented as correlation coefficient (r) or
mean ± standard deviation.
bPearson correlation test
cIndependent two-sample t-test
dAnalysis of variance
e50 patients with non-Hodgkin lymphoma and one with sarcoma were included.
*P < 0.05
https://doi.org/10.1371/journal.pone.0179986.t004
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diabetic mice [41]. In that study, the wound-healing effect of relaxin was disturbed by antibod-
ies against vascular endothelial growth factor, CXCR4, and CXCR12 [41]. Our data support
previous assumptions about the effects of relaxin on vasculogenic capacity and stem cell/pro-
genitor cell regulation, and suggest a broader applicability of relaxin to other vascular disorders
such as diabetes mellitus. In addition, our data also suggest that relaxin is a novel agent for the
management of poor mobilizers.
Among host risk factors, female sex, history of multiple chemotherapy regimens, and diag-
nosis of acute leukemia remained independently associated with low circulating CD34+ cell
counts in Koreans. Female sex [4,42], prior treatment history [1], and diagnosis of acute leuke-
mia [43] have all been known to be independent risk factors for poor mobilization. The mech-
anism behind association of sex and better mobilization potential can be explained by the stem
cell regulation effect of sex steroids [44]. The contribution of an underlying hematologic dis-
ease on HSC mobilization can be explained by disease-related reduction of HSC reservoir, or
chemotherapy-induced toxic effects on BM [43]. In the European set, only BMI correlated
with circulating CD34+ cell counts. The mechanism behind association between higher BMI
and better mobilization potential has been attributed to the effect of adipose tissue-containing
HSCs, or a simple dose effect of G-CSF [8].
To the best of our knowledge, this is the first study to indicate an association between
relaxin receptor polymorphism and HSC yield after mobilization. A potential limitation of our
study is that the discovered locus is located in the regulatory region of RXFP4, and not in the
protein-coding region. Further investigation regarding the functional effect of relaxin-3, as
well as its receptor axis on the mobilization process, are required.
In conclusion, we found a novel association between relaxin receptor polymorphism and
HSC yield after mobilization in ethnic Koreans. Our findings suggest an important functional
role of relaxin axis during response of BM HSCs to the mobilizing agent. Results of our study
Table 5. Factors associated with log-transformed mobilization outcomes in the multivariate linear regression analysis in the Korean set.
Variables CD34+ cells/μL in PB CD34+ cells/kg (×106) CD34+ cells/μL in a product
β (95% CI) P value β (95% CI) P value β (95% CI) P value
Sex
Male Reference Reference Reference
Female -0.660 (-1.028, -0.292) 0.001* -0.630 (-1.018, -0.242) 0.002* -0.590 (-0.987, -0.193) 0.004*
Body-mass index (kg/m2) 0.025 (-0.031, 0.081) 0.4
Diagnosis
Healthy donor Reference Reference
Acute leukemia -1.722 (-2.545, -0.898) <0.001* -1.737 (-2.574, -0.901) <0.001*
Non-Hodgkin lymphoma/sarcomaa -0.259 (-0.701, 0.183) 0.2 -0.368 (-0.803, 0.068) 0.09
Multiple myeloma -0.057 (-0.551, 0.437) 0.8 -0.150 (-0.653, 0.353) 0.6
Chemotherapy regimen history
Multiple regimens (three or more) Reference
One or two regimens 0.877 (0.100, 1.654) 0.03*
RXFP4 genotype
TT Reference Reference Reference
TA 0.091 (-0.405, 0.588) 0.7 0.166 (-0.347, 0.678) 0.5 0.122 (-0.382, 0.626) 0.6
AA 1.735 (0.446, 3.024) 0.009* 1.809 (0.452, 3.166) 0.009* 1.830 (0.526, 3.135) 0.006*
PB, peripheral blood; CI, confidence interval
a50 patients with non-Hodgkin lymphoma and one with sarcoma were included.
*P < 0.05
https://doi.org/10.1371/journal.pone.0179986.t005
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give valuable insight to a potential therapeutic target—the relaxin—relaxin receptor axis—for
the management of poor mobilizers, and for the treatment of various vascular diseases.
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S1 File. Table A. Association of 53 polymorphisms with mobilization outcomes.
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